Ask AI
ProCE Banner Activity

PURPOSE 1 and PURPOSE 2: Efficacy, Safety, and PK of Twice-Yearly Subcutaneous Lenacapavir for PrEP in Adolescents and Young Adults

Conference Coverage
Slideset

PrEP with lenacapavir was safe and well tolerated in people aged 16-25 years, with pharmacokinetic profiles largely consistent with those observed in adults, supporting the extrapolation of efficacy to youth.

Released: July 22, 2025

Expiration: January 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner